| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
PHARMACOKINETICS |
From PTC Therapeutics, Inc, South Plainfield, New Jersey.
Nonsense (premature stop codon) mutations are causative in 5% to 15% of patients with monogenetic inherited disorders. PTC124, a 284-Dalton 1,2,4-oxadiazole, promotes ribosomal readthrough of premature stop codons in mRNA and offers therapeutic potential for multiple genetic diseases. The authors conducted 2 phase I studies of PTC124 in 62 healthy adult volunteers. The initial, single-dose study evaluated doses of 3 to 200 mg/kg and assessed fed-fasting status on pharmacokinetics following a dose of 50 mg/kg. The subsequent multiple-dose study evaluated doses from 10 to 50 mg/kg/dose twice per day (bid) for up to 14 days. PTC124 administered orally as a liquid suspension was palatable and well tolerated through single doses of 100 mg/kg. At 150 and 200 mg/kg, PTC124 induced mild headache, dizziness, and gastrointestinal events. With repeated doses through 50 mg/kg/dose bid, reversible transaminase elevations <2 times the upper limit of normal were sometimes observed. Immunoblot analyses of peripheral blood mononuclear cell extracts revealed no protein elongation due to nonspecific ribosomal readthrough of normal stop codons. PTC124 plasma concentrations exceeding the 2- to 10-µg/mL values associated with activity in preclinical genetic disease models were safely achieved. No sex-related differences in pharmacokinetics were seen. No drug accumulation with repeated dosing was apparent. Diurnal variation was observed, with greater PTC124 exposures after evening doses. PTC124 excretion in the urine was <2%. PTC124 pharmacokinetics were described by a 1-compartment model. Collectively, the data support initiation of phase II studies of PTC124 in patients with nonsense mutation–mediated cystic fibrosis and Duchenne muscular dystrophy.
Key Words: PTC124 • nonsense mutation • genetic disease • phase I clinical trial • pharmacokinetics
Address for reprints: Langdon L. Miller, MD, Chief Medical Officer, PTC Therapeutics, Inc, 100 Corporate Court, South Plainfield, NJ 07080; e-mail: lmiller{at}ptcbio.com.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  A Y Manzur and F Muntoni Diagnosis and new treatments in muscular dystrophies Postgrad. Med. J., November 1, 2009; 85(1009): 622 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. B. Mattis, A. D. Ebert, M. Y. Fosso, C.-W. Chang, and C. L. Lorson Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model Hum. Mol. Genet., October 15, 2009; 18(20): 3906 - 3913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Du, R. Damoiseaux, S. Nahas, K. Gao, H. Hu, J. M. Pollard, J. Goldstine, M. E. Jung, S. M. Henning, C. Bertoni, et al. Nonaminoglycoside compounds induce readthrough of nonsense mutations J. Exp. Med., September 28, 2009; 206(10): 2285 - 2297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Carrier, S. Schlossarek, M. S. Willis, and T. Eschenhagen Ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy Cardiovasc Res, August 10, 2009; (2009) cvp247v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Teng, L. Gao, V. Paajanen, J. Pu, and Z. Fan Readthrough of nonsense mutation W822X in the SCN5A gene can effectively restore expression of cardiac Na+ channels Cardiovasc Res, August 1, 2009; 83(3): 473 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Y Manzur and F Muntoni Diagnosis and new treatments in muscular dystrophies J. Neurol. Neurosurg. Psychiatry, July 1, 2009; 80(7): 706 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Heier and C. J. DiDonato Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo Hum. Mol. Genet., April 1, 2009; 18(7): 1310 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Moosajee, K. Gregory-Evans, C. D. Ellis, M. C. Seabra, and C. Y. Gregory-Evans Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease Hum. Mol. Genet., December 15, 2008; 17(24): 3987 - 4000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Liu, P. Margaritis, F. Khazi, H. Downey, S. Kadauke, N. Hasbrouck, J. Sheedy, E. Welch, M. Weetall, and K. A. High Nonsense Suppression Approaches in Treating Hemophilia Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 512 - 512. [Abstract]
|
|
|
|
 |
|
 D. Bilton What did we learn from the North American Cystic Fibrosis Conference? J R Soc Med, July 1, 2008; 101(Supplement_1): 6 - 9. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Du, X. Liu, E. M. Welch, S. Hirawat, S. W. Peltz, and D. M. Bedwell PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model PNAS, February 12, 2008; 105(6): 2064 - 2069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. High Update on Progress and Hurdles in Novel Genetic Therapies for Hemophilia Hematology, January 1, 2007; 2007(1): 466 - 472. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
